DeDora Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,314
Closed -$118K 394
2022
Q1
$118K Buy
+1,314
New +$121K 0.05% 112
2021
Q4
Sell
-2,628
Closed -$330K 113
2021
Q3
$330K Hold
2,628
0.14% 79
2021
Q2
$356K Buy
2,628
+195
+8% +$25.6K 0.16% 78
2021
Q1
$330K Buy
2,433
+33
+1% +$4.94K 0.16% 78
2020
Q4
$338K Buy
2,400
+12
+0.5% +$1.54K 0.17% 75
2020
Q3
$266K Buy
+2,388
New +$268K 0.15% 83

Other funds holding XBI

DeDora Capital's XBI Position: Q2 2022 in Review

DeDora Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 1,314 shares — an estimated $118K sold.

DeDora Capital first reported a position in XBI in Q3 2020 and held it in 6 quarters. The position peaked at $356K in Q2 2021. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

  • DeDora Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
  • DeDora Capital sold 1,314 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $118K.
  • DeDora Capital first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 6 quarters.
  • DeDora Capital's State Street SPDR S&P Biotech ETF position peaked at $356K in Q2 2021.
  • 706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on DeDora Capital's 13F filing for Q2 2022, filed 27 Jul 2022.